Increased access to human genetic data and the rise of CRISPR/Cas9 has led to rapid changes in the field of target validation. Recognizing the significance of these changes, we are bringing together researchers who share an interest in this important foundational step in the drug discovery process at our Translational Target Validation Symposium. We will discuss the latest advances and technology in target drug discovery that can provide a path to better drugs.
This educational event will be held on Tuesday, 20 June 2017, at the Wellcome Genome Campus Conference Center on the Hinxton Hall Estate near Cambridge, UK. This event is complimentary. In lieu of charging a registration fee, Charles River will donate £25 to Cancer Research UK for each registrant who registers and attends the event.*
Register Now »
* Up to a donation of £2500.